Ad is loading...
ARWR
Price
$18.79
Change
-$0.00 (-0.00%)
Updated
Nov 25 closing price
Earnings call today
UCBJY
Price
$96.45
Change
-$0.00 (-0.00%)
Updated
Nov 25 closing price
93 days until earnings call
Ad is loading...

ARWR vs UCBJY

Header iconARWR vs UCBJY Comparison
Open Charts ARWR vs UCBJYBanner chart's image
Arrowhead Pharmaceuticals
Price$18.79
Change-$0.00 (-0.00%)
Volume$1.51M
CapitalizationN/A
UCB S.A
Price$96.45
Change-$0.00 (-0.00%)
Volume$17.08K
CapitalizationN/A
ARWR vs UCBJY Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
UCBJY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ARWR vs. UCBJY commentary
Nov 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and UCBJY is a StrongBuy.

COMPARISON
Comparison
Nov 27, 2024
Stock price -- (ARWR: $18.79 vs. UCBJY: $96.45)
Brand notoriety: ARWR: Notable vs. UCBJY: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 134% vs. UCBJY: 74%
Market capitalization -- ARWR: $2.34B vs. UCBJY: $35.78B
ARWR [@Biotechnology] is valued at $2.34B. UCBJY’s [@Biotechnology] market capitalization is $35.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $463.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileUCBJY’s FA Score has 3 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • UCBJY’s FA Score: 3 green, 2 red.
According to our system of comparison, UCBJY is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 3 TA indicator(s) are bullish while UCBJY’s TA Score has 6 bullish TA indicator(s).

  • ARWR’s TA Score: 3 bullish, 7 bearish.
  • UCBJY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, UCBJY is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а -1.21% price change this week, while UCBJY (@Biotechnology) price change was +10.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +13.39%. For the same industry, the average monthly price growth was +3.80%, and the average quarterly price growth was +9.29%.

Reported Earning Dates

ARWR is expected to report earnings on Feb 05, 2025.

UCBJY is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (+13.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
UCBJY($35.8B) has a higher market cap than ARWR($2.34B). UCBJY YTD gains are higher at: 123.624 vs. ARWR (-38.595). UCBJY has higher annual earnings (EBITDA): 1.12B vs. ARWR (-508.26M). UCBJY has more cash in the bank: 689M vs. ARWR (434M). ARWR has less debt than UCBJY: ARWR (118M) vs UCBJY (3.04B). UCBJY has higher revenues than ARWR: UCBJY (5.45B) vs ARWR (19.6M).
ARWRUCBJYARWR / UCBJY
Capitalization2.34B35.8B7%
EBITDA-508.26M1.12B-45%
Gain YTD-38.595123.624-31%
P/E RatioN/A150.89-
Revenue19.6M5.45B0%
Total Cash434M689M63%
Total Debt118M3.04B4%
FUNDAMENTALS RATINGS
ARWR vs UCBJY: Fundamental Ratings
ARWR
UCBJY
OUTLOOK RATING
1..100
2271
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
10016
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
8339
P/E GROWTH RATING
1..100
28
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UCBJY's Valuation (2) in the null industry is significantly better than the same rating for ARWR (95) in the Biotechnology industry. This means that UCBJY’s stock grew significantly faster than ARWR’s over the last 12 months.

UCBJY's Profit vs Risk Rating (16) in the null industry is significantly better than the same rating for ARWR (100) in the Biotechnology industry. This means that UCBJY’s stock grew significantly faster than ARWR’s over the last 12 months.

UCBJY's SMR Rating (95) in the null industry is in the same range as ARWR (98) in the Biotechnology industry. This means that UCBJY’s stock grew similarly to ARWR’s over the last 12 months.

UCBJY's Price Growth Rating (39) in the null industry is somewhat better than the same rating for ARWR (83) in the Biotechnology industry. This means that UCBJY’s stock grew somewhat faster than ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is in the same range as UCBJY (8) in the null industry. This means that ARWR’s stock grew similarly to UCBJY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRUCBJY
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
58%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
55%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
51%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
50%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
65%
Declines
ODDS (%)
Bearish Trend 12 days ago
83%
Bearish Trend 8 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
39%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
UCBJY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSZAX5.970.07
+1.19%
NexPoint Climate Tech A
SJCIX31.900.29
+0.92%
Steward Large Cap Core I
FMSTX37.510.21
+0.56%
Federated Hermes MDT Large Cap Value IS
FDFIX25.600.08
+0.31%
Fidelity Flex 500 Index
MIGWX28.19-0.05
-0.18%
Marsico Growth Institutional

UCBJY and

Correlation & Price change

A.I.dvisor tells us that UCBJY and GBIO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that UCBJY and GBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UCBJY
1D Price
Change %
UCBJY100%
+2.89%
GBIO - UCBJY
28%
Poorly correlated
+2.19%
VANI - UCBJY
26%
Poorly correlated
+2.24%
ABOS - UCBJY
24%
Poorly correlated
-0.42%
TNYA - UCBJY
23%
Poorly correlated
+24.37%
ARWR - UCBJY
23%
Poorly correlated
+1.35%
More